Psychological distress is linked to metabolic alterations that may contribute to adverse cardiometabolic outcomes. A previously developed metabolite-based distress score (MDS)—derived primarily in White women—was shown to associate with distress. Given higher cardiometabolic disease burdens among men and Black individuals, the investigators assessed whether the original MDS performs similarly across racial groups and sexes and sought to derive a multi-ethnic MDS (MDS-ME) that better generalizes to Black participants.
The analysis used data from three US cohort studies: the Multi-Ethnic Study of Atherosclerosis (MESA), the Women's Health Initiative (WHI), and the Nurses' Health Study (NHS). Baseline plasma metabolomics and depression status data were available for MESA participants and were central to the multi-stage analytic plan. Sample sizes reported for MESA included 2,477 White and 1,625 Black participants with available data.
The investigation proceeded in four stages:
When the original 20-metabolite MDS was applied to MESA data, the score was more strongly associated with prevalent depression among White participants than among Black participants. Reported effect estimates were an odds ratio (OR) of 1.93 (95% CI 1.71–2.19) in White participants and an OR of 1.13 (95% CI 0.97–1.33) in Black participants. Associations were generally similar when stratified by sex (men and women), according to the source report.
To identify metabolites that may improve score performance in Black participants, the authors conducted an agnostic metabolomics analysis in a randomly selected 70% subset of Black MESA participants. The source reports that this stage aimed to discover additional metabolites associated with depression in Black individuals; specific metabolites identified in this agnostic analysis are not listed in the source summary.
Using metabolites identified among Black participants, the investigators derived an expanded MDS-ME comprising 33 metabolites. The MDS-ME was designed to better capture metabolic signatures of distress in a more diverse population than the original score.
The derived MDS-ME was evaluated in independent samples from all three cohorts. In MESA Black participants, the MDS-ME showed a stronger association with prevalent depression compared with the original MDS, with an OR of 1.45 (95% CI 1.04–2.03). The MDS-ME also retained associations in White participants (OR 1.81, 95% CI 1.60–2.04). Additionally, associations were observed in Black women in replication samples from WHI and NHS, according to the source.
Specific metabolite names included in either the original MDS or the MDS-ME are not enumerated in the source abstract. The source does report that the MDS-ME comprises 33 metabolites but does not list them in the summary provided.
The authors conclude that incorporating metabolites identified in Black participants enhances the utility and generalizability of a metabolite-based distress score across more diverse US populations. Expanding a metabolomic distress score to include metabolites relevant to understudied populations may improve identification of metabolic correlates of psychological distress and potentially improve risk stratification for related cardiometabolic outcomes.
The research received ethical approval from the IRB of the University of Massachusetts Amherst, and participant consent procedures were followed. Funding declared includes grants from the National Institutes of Health and support from USDA/ARS. One author reported a consulting relationship with Westat; all other authors reported no biomedical financial interests or potential conflicts of interest. The source indicates that all study data are contained in the manuscript.